The objective of this mechanistic study is to determine the impact of tecemotide (L-BLP25)
administration on the mucinous glycoprotein 1 - (MUC1) specific immune response in subjects
with newly diagnosed rectal cancer who are eligible for neoadjuvant therapy.
Tecemotide (L-BLP25) is designed to induce an immune response that may lead to immune
rejection of tumor tissues that aberrantly express MUC1 antigen. MUC1 is highly expressed in
all colorectal cancers and since the adaptive immune system plays a role in the prognosis of
rectal cancer, it is reasonable to speculate that tecemotide (L-BLP25) administration might
boost the tumor-specific immune response and increase the number of tumor-infiltrating
lymphocytes (TILs).
Phase:
Phase 2
Details
Lead Sponsor:
Merck KGaA Merck KGaA, Darmstadt, Germany
Treatments:
Cyclophosphamide Molecular Mechanisms of Pharmacological Action